Entasis Anticipates First FDA Approval Of Pathogen-Specific Antibacterial
Executive Summary
With Phase III data showing non-inferiority to colistin, as well as nephrotoxicity superiority, Entasis thinks sulbactam/durlobactam will provide a new standard of care and succeed where Achaogen’s Zemdri failed.
You may also be interested in...
IDWeek 2022 Notebook: Entasis Bolsters Case For SUL-DUR Antibiotic Combo
Entasis is hoping for a pathogen- rather than location-specific indication for sulbactam-durlobactam (SUL-DUR) in the US. Gilead’s Veklury remains a standard-of-care COVID-19 treatment. Summit claims further analysis of failed ridinilazole Phase III study shows recurrence advantage versus vancomycin.
Innoviva Aims For Antibiotic Success With La Jolla, Entasis Acquisitions
Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.